Last reviewed · How we verify

Niktimvo — Competitive Intelligence Brief

Niktimvo (AXATILIMAB) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Colony Stimulating Factor-1 Receptor Blocker [EPC]. Area: Immunology.

marketed Colony Stimulating Factor-1 Receptor Blocker [EPC] Immunology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Niktimvo (AXATILIMAB) — Incyte Corp. Niktimvo blocks the Colony Stimulating Factor-1 Receptor to reduce inflammation and prevent damage to healthy tissues.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Niktimvo TARGET AXATILIMAB Incyte Corp marketed Colony Stimulating Factor-1 Receptor Blocker [EPC] 2024-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Colony Stimulating Factor-1 Receptor Blocker [EPC] class)

  1. Incyte Corp · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Niktimvo — Competitive Intelligence Brief. https://druglandscape.com/ci/axatilimab. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: